Linkage studies suggest that chromosome 22q12-13 may contain one or more shared susceptibility genes for schizophrenia (SZ) and bipolar affective disorder (BPD). In a Faeroese sample, we previously reported association between microsatellite markers located at 22q13.31-qtel and both disorders. The present study reports an association analysis across five genes (including 14 single nucleotide and two microsatellite polymorphisms) in this interval using a case-control sample of 162 BPD, 103 SZ patients and 200 controls. The bromodomain-containing 1 gene (BRD1), which encodes a putative regulator of transcription showed association with both disorders with minimal P-values of 0.0046 and 0.00001 for single marker and overall haplotype analysis, respectively. A specific BRD1 2-marker 'risk' haplotype showed a frequency of B10% in the combined case group versus B1% in controls (P-value 2.8 Â 10
Introduction
Bipolar affective disorder (BPD) and schizophrenia (SZ) are both lifelong disabling psychiatric disorders with a significant genetic component in their complex etiology.
1,2 Shared epidemiologic and clinical characteristics suggest overlap in susceptibility for the two disorders. 3 Estimates of their heritability are comparable (around 70%) and family studies have shown an increased risk for schizoaffective disorder and depression among first-degree relatives of both bipolar and schizophrenia probands. 3 In accordance with these observations, evidence from linkage studies indicates that several chromosomes may harbor shared susceptibility loci for BPD and SZ, e.g. 4p16, 8p22, 10p14, 13q32, 18p11 and 22q11-13. [4] [5] [6] [7] Several studies have suggested linkage of especially SZ but also BPD to a number of regions on chromosome 22. 8 This has been supported by meta-analyses. 9, 10 The meta-analysis by Badner and Gershon, 9 in particular, examined 11 BPD and 18 SZ genome scans, using the Multiple Scan Probability method that combines P-values from linkage regions with clusters of positive results, and found 22q to be one of two regions showing the most significant evidence for linkage in both disorders (P < 1 Â 10 À5 for BPD, and P < 9 Â 10 À5 for SZ). At the telomeric region of 22q, Coon et al. 11 originally found evidence of linkage to marker D22S55 at 22q13.33 (APM P-value 0.003) in a genome scan of nine SZ families. More recently, positive linkage to D22S1169 at 22q13.32 was reported for a subset of pedigrees in a multicenter study of 779 SZ pedigrees, and with borderline significance in the total sample when intersample heterogeneity was taken into account. 12 Likewise, Takahashi et al. 13 reported suggestive linkage to D22S1169 in subsets of highly familial SZ pedigrees, and a genome scan of catatonic SZ pedigrees found a maximal multipoint LOD score of 2.59 at D22S1169. 14 In BPD linkage has mostly been reported (and examined) at more centromeric regions. In the study of Kelsoe et al., 15 the most significant linkage was found at D22S278 (22q12.3), but positive LOD scores (0.58- 1.22) were also reported at the most telomeric markers tested at 22q13.2-q13. 31 .
In a study of distantly related cases and controls from the Faeroe Islands our group has previously reported that chromosome 22q13 may harbor two shared susceptibility loci for BPD and SZ, the most distal locus located telomeric to D22S1170 (22q13. 31-qtel) . 16 In the present study, we carried out an association analysis of five brain-expressed genes located in this telomeric region, using a case-control sample from Scotland. One of the genes, the bromodomain-containing 1 gene (BRD1), showed association with both disorders and the gene was further characterized by expression analyses and immunohistochemical studies of adult mammalian brain samples (including human) and fetal pig brain.
Materials and methods

Subjects
The case-control sample from Scotland consisted of 103 patients with SZ, 162 patients with BPD and 200 ethnically matched controls. Informed consent was obtained from all patients prior to inclusion, and the study was approved by the local research ethical committees where patients were recruited. Subjects were interviewed by an experienced psychiatrist and venous blood taken for subsequent DNA extraction using routine procedures. Diagnoses were made according to DSM-IV criteria after case-note review and personal interview using the Schedule for Affective Disorders and Schizophrenia -Lifetime version. Final diagnoses were reached by consensus between two experienced psychiatrists (DB and WM). Control subjects (prescreened to exclude those with serious chronic illness) were drawn from the same population in South East and South Central Scotland and recruited from Scottish National Blood Transfusion Service donors. We have reported these sample sets previously.
17,18
Genotyping
The genes selected were included on the basis of their location, expression profile and existing knowledge of their function. The selection criteria for the single nucleotide polymorphisms (SNPs) were also based on a functional approach evaluating the type of SNP (prioritizing nonsynonymous SNPs) and location (preferably promoter, UTR, intron/exon boundaries, and conserved regions). Genotyping was performed using 40 ng of DNA per multiplex PCR. Exonuclease1 and Shrimp Alkaline Phosphatase were used for purification steps and the SNPs genotyped by multiplex single base extension technology using the ABI SNaP-shot kit and an ABI 310 Genetic Analyzer or a 3100 Avant Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's recommendations. The data was analyzed using the GeneScan 3.1.2 program (Applied Biosystems, Foster City, CA, USA). Standard PCR conditions were used. The microsatellite markers were analyzed using fluorescent primers, standard conditions for (duplex) PCR amplification and separation of allelic fragments on an ABI 310 Genetic Analyzer. All primer sequences are available on request. To minimize genotyping errors all polymorphisms were scored independently by two experienced investigators. Any discordances lead to re-analysis of the sample. In addition a number of SNPs (including BRD1 rs4468 and rs138880) were analyzed twice in at least 85 individuals. No divergent genotypes were observed, indicating a very low error rate (for allele calls < 0.006). 19 When comparing two groups, HTR produces an overall P-value for the observed distribution of all the haplotypes at an interval defined by a set of neighboring markers and also a haplotype-specific P-value describing the likelihood of the observed distribution of each of the individual haplotypes. The P-values from HTR presented in this study are empirical values based on upto 100 000 000 permutations. P-values < 0.05 are referred to as significant. The P-values presented are not corrected for multiple testing. However, the highly significant haplotype associations remained significant even after a Bonferroni correction, which is overly conservative as the tests performed are not independent.
Statistical analysis
Tests of linkage disequilibrium were performed using the program Ldmax from the GOLD software package (http://www.sph.umich.edu/csg/abecasis/ GOLD) which uses the Slatkin and Excoffier expectation-maximization based approach. 20 In silico analysis The impact of a promoter SNP on potential binding sites for transcription factors was analyzed using the program MatInspector (www.genomatix.de). 21, 22 This program utilizes a library of matrix descriptions for transcription factor binding sites to identify potential sites in a sequence analyzed and assign a quality rating of matches (core and matrix similarity) estimating the influence of a SNP on the binding of transcription factors.
The possible effect of an intragenic SNP on splicing was investigated using the programs ESEfinder release 2.0 (http://rulai.cshl.edu/tools/ESE), [21] [22] [23] RES-CUE-ESE Web Server (http://genes.mit.edu/burgelab/ rescue-ese), 24 FAS-ESS web server (http://genes.mit. edu/fas-ess/), 25 ExonScan Web Server (http://genes. mit.edu/exonscan/) [24] [25] [26] and NNSPLICE (http:// www.fruitfly.org/seq_tools/splice). 27 The effects of 3 0 UTR SNPs on microRNA binding sites were analyzed using the miRBase Targets Prerelease Version 1.0 (http://microrna.sanger.ac.uk/ targets/v1/) which is a web resource provided by the Wellcome Trust Sanger Institute containing computationally predicted targets for microRNAs across a number of species.
Northern blotting
Human Multiple Tissue Northern Blots II and V (Clontech Laboratories, CA, USA) were probed with a a-32 P-CTP-labeled probe against BRD1. Full-length BRD1 was cloned from human brain cDNA (Clontech, #639300), gel purified (Qiagen, #28704) and used as template for the probe synthesis. The probe was synthesized and labeled using 15 000 C i /mmol a-32 P-CTP (EasyTides) and the Prime-It RmT Random Primer Labeling Kit (Stratagene, #300392) following the manufacturer's protocol. The specific activity of the probe was measured to 1.3 Â 10 9 dpm/mg. The blots were hybridized and rinsed as described previously 28 and exposed to X-ray film for 3 weeks.
Preparation of rat, rabbit, human and fetal pig brain tissue Seven male Wistar rats (250-300 g) and five male New Zealand white rabbits (2.5-3.5 kg) were deeply anesthetized before transcardial perfusion with 0.5 l (rats) or 1.5 l (rabbits) phosphate-buffered 4% paraformaldehyde (pH 7.4) at 41C as approved by the Danish Council for Animal Research Ethics. The brains were immersed in the same fixative for 24 h and divided into two to three minor coronal tissue blocks by histOmer embedding and sectioning on a HistOtech slicer 29 before vibratome sectioning into 50 mm sections. Human brain tissue was obtained from two donors who had donated their remains for educational and scientific purposes at the Institute of Anatomy, University of Aarhus. The brains were removed 24-72 h postmortem and briefly stored in 10% formalin before smaller tissue blocks containing the frontal cortex were paraffin-embedded and microtome sectioned into 10 mm sections.
Fetal pig brain tissue was obtained from pregnant sows anesthetized by carbon dioxide and killed by bleeding at embryonic day 40, 60, 80, 100 and 115, respectively. The removed fetal brain tissue was briefly immersed in 10% formalin before tissue blocks containing the forebrain (cortex cerebri) and the hindbrain (lower brainstem and cerebellum) were embedded in paraffin and microtome sectioned into 2 mm sections.
For quantitative analysis of the mRNA expression, the hippocampus, cortex, basal ganglia, cerebellum and brain stem were dissected from the fetal brains and immediately frozen in liquid nitrogen. After thawing on ice, total RNA was extracted with Totally RNAt (Ambion) according to the manufacturer's protocol.
Immunohistochemistry
The anti-BRD1 monoclonal antibody used was provided by Bryan Young and was identical to that used in the initial BRD1 cloning study. 30 It was raised against the 11 amino acid peptide RRPFSWEDVDR corresponding to amino acids 692-702 of BRD1.
Vibratome and cryostat sections were initially blocked for endogenous biotin before preincubation with 1% Triton X-100 and 0.2% milk (Bidinger, Denmark) in TBS for 30 min followed by incubation at 41C with the primary monoclonal antibody (mouse anti-BRD1) diluted 1:500-1:1000 in TBS containing 1% Triton X-100 and 0.2% milk for 72 h. After rinsing with TBS and 1% Triton X-100 for 3 Â 15 min, the sections were incubated for 1 h at room temperature with the secondary antibody (sheep anti-mouse Ig biotin-labeled, Amersham, RPN 1001) diluted 1:200-1:400 in TBS containing 1% Triton X-100 and 0.2% milk. Endogenous peroxidase activity was blocked with a solution of 80 ml TBS with 10 ml H 2 O 2 and 10 ml methanol for 10 min. Avidin-peroxidase (Sigma: A 3151) diluted 1:200-1:400 with TBS containing 1% Triton X-100 and 0.2% milk was then applied for 1 h at room temperature. After rinsing for 3 Â 15 min in TBS þ 1% Triton X-100, the formed avidin-peroxidase complexes were visualized by incubation for 10 min with diaminobenzidine (DAB) made by dissolving a 10 mg DAB-tablet (Kem-En-Tec Diagnostics A/S) in 10 ml water and immediately before use adding 10 ml of 35% H 2 O 2 . After mounting and coverslipping with Depex, the sections were analyzed using a light microscope and compared with Nissl-stained sections, securing systematic analysis of consecutive coronal brain levels.
Paraffin-embedded sections were stained according to the above mentioned protocol after initial target retrieval by microwave boiling of the sections for 10 min in a citrate buffer (pH = 6.0) and usage of the primary monoclonal mouse anti-BRD1 antibody diluted 1:150.
Double immunofluorescence staining was performed on vibratome sections incubated for 72 h at 41C with the primary monoclonal BRD1 antibody diluted 1:500, followed by a 1 h incubation at room temperature with the secondary antibody (goat antimouse Ig FITC-labeled, Abcam, ab6785) diluted 1:600. The sections were then treated with 500 mg RNaseA (Roche, 109 142) for 20 min, before nuclear staining with TO-PRO-3 (Molecular Probes, T3605) diluted 1:1000 for 5 min, followed by mounting and coverslipping with Vecta-shield H1000 and subsequent confocal microscopic analysis.
cDNA synthesis and real-time qPCR cDNA was synthesized from 1 mg total RNA in 20 ml reactions using iScript cDNA synthesis Kit (Biorad). After synthesis the cDNA was diluted five times with double-distilled water. The real-time RT-PCR reactions were made with DyNAmoSYBR Green qPCR kit (Finnzymes) in a total volume of 20 ml, using 6 pmol primers specific for pig BRD1 (forward: 5 0 -GGGCCAAGTGCAGCGGCTAC-3 0 , reverse: 5 0 -CTCCATCATCTTCAGCTTGTC). Amplification was carried out on a Biorad iCycler using the following conditions: 951C 15 min, (941C 10 s, 581C 20 s, 721C 30 s) 40 repeats, 721C 10 min, cooled to 201C. PCR specificity was controlled by melting curve analysis. All reactions were also run using primers specific for pig-GAPDH as an internal standard (forward: 5 0 -GGGGAATTCGCCACCATGGTGAAGGT CGGAGTGAAC-3 0 , reverse: 5 0 -GGGGAATTCGATGA CAAGCTTCCCATTCTC-3 0 ). The relative standard curve for the real-time qPCR reactions were made from RT-PCR of cDNA from the 115-day-old fetus hippocampus, amplified with the above-mentioned conditions. The product was run on a 1% agarose gel, cut out and purified using QIAquick Gel Extraction Kit Protocol (Qiagen). The DNA was diluted and used to produce a relative standard curve showing above 90% PCR efficiency in the area. The specificity of the PCR product was verified by sequencing showing the position of the product to span the last two exons of the gene. Relative quantification of the expression was determined as follows. Three replicates of the threshold cycle for BRD1 (C T,X ) and GAPDH (C T,R ) were measured. Subtracting each C T,R replicate from each C T,X nine threshold differences (DC T ) were calculated. Under assumptions of normality and variance homogeneity the temporal change in expression was examined by analysis of variance contrasting to embryonic day 115 the mean threshold difference from each of the other days. P-values are adjusted for the number of contrasts tested using the Sidák method. Note this analysis is a variant of the 2 ÀDDC T method 31 with DDC T equal to the contrasts and results are presented in terms of fold changes 2 ÀDDC T ( Figure 5 ). Moreover, a polynomial regression model up to third order was determined using a forward inclusion stepwise procedure. The significance of the highest order term is indicated and the resulting regression curve with 95% confidence bands is shown after back-transformation by 2 ÀDC T ( Figure 5 ).
Results
Association analysis
Five SNPs in BRD1, nine SNPs in four neighboring genes and two microsatellite markers were selected and genotyped in a Scottish case-control sample, including 103 SZ cases, 162 BPD cases, and 200 controls (Table 1) . Rs3752466 turned out to be constant and was consequently excluded from further analysis. No significant deviation from Hardy-Weinberg equilibrium was observed for any of the SNPs in the case or control groups. Single-marker and multimarker haplotype analysis was performed comparing controls to SZ, BPD, and the two case groups combined. Significant single-marker associations were observed for two BRD1 SNPs and D22S1169 ( Table 2) . The promoter SNP rs138880 showed association in SZ, BPD and the combined case group with P-values of 0.0061, 0.0274 and 0.0046, respectively. The 3 0 UTR SNP rs4468 and D22S1169 showed significant association with SZ (P = 0.0088 and 0.0214, respectively) but not with BPD. These allelic associations were also found in the analysis of the genotypic distribution with similar P-values (results not shown).
The haplotype analysis considering the overall distribution of all haplotypes of two to four neighboring markers in a sliding window fashion showed comparable results in both disorders (Table 2) . Highly significant overall P-values (as low as 0.00001) were observed in especially the 3-and 4-marker analysis involving the BRD1 SNPs rs138855, rs2239848, rs138880 and rs138881. Haplotypes involving the microsatellite markers and the proximal BRD1 SNPs showed primarily association in SZ. Analysis of the individual haplotypes revealed that the overall association could be attributed to both 'risk' and 'protective' haplotypes (Table 3) . A 3-marker core haplotype spanning BRD1 SNPs rs138855, rs2239848 and rs138880 had a frequency of around 9% in cases against only 1% in controls, producing a haplotype specific P-value of order 10 À6 . Removing the rare middle SNP rs2239848 from the analysis resulted in a reduced 2-marker 'risk' haplotype (G-C) showing a frequency of B10% in cases versus B1% in controls (P-value of 2.8 Â 10 À7 in the combined case group). Five individuals were homozygous for this haplotype, all of whom were suffering from BPD. Thus, the allelic/haplotypic association was based on a preponderance of both hetero-and homozygotes among cases.
'Protective' haplotypes over-represented among controls included both microsatellites, all the BRD1 SNPs and extended into MLC1 (megalencephalic leukoencephalopathy with subcortical cysts 1) ( Table  3) . These related and rather frequent haplotypes showed primarily significant results when compared to their frequencies in SZ.
Linkage disequilibrium A high degree of inter-marker linkage disequilibrium (LD) between the SNPs in BRD1 was found in controls and cases (Table 4) . Likewise a high LD between the SNPs in MLC1 extending distally to MOV10L1 (Moloney leukemia virus 10-like 1, homolog (mouse)) was seen in both cases and controls. No significant LD was seen between BRD1 and MLC1.
In silico analysis Using MatInspector, the two promoter SNPs in BRD1 (Table 1) were analyzed for potential effects on binding sites for transcription factors. The C-allele of rs138880 introduced binding sites for two transcription factors: The zinc-finger binding protein factor encoded by ZNF202 which is thought to predominantly regulate genes participating in lipid metabolism, 32 and hairy and enhancer of split homolog 1 (HES-1) (showing a high core and matrix similarity), which is a transcriptional repressor inhibiting neural differentiation. 33 Rs138881 did not introduce any changes.
The synonymous BRD1 SNP rs2239848 located in exon 1 was analyzed for effects on exon splicing enhancers (ESE) and exon splicing silencers (ESS). According to ESEfinder the presence of the rare Aallele eliminated a binding site for the SR protein SRp55. However, analysis of the splice site in exon 1 revealed a very strong donor site thus suggesting a very limited potential effect of exon 1 ESEs. Neither RESCUE-ESE nor FAS-ESS identified any effect of rs2239848 on splicing.
Analysis of intronic and 3 0 UTR SNPs did not suggest any differential effects of the alleles.
Northern blotting A BRD1 transcript of the expected size (approximately 4.6 kb). was observed in most of the human brain regions tested, that is, whole brain, cerebellum, cerebral cortex, medulla, spinal cord, occipital pole, frontal lobe, caudate nucleus, corpus callosum, hippocampus and thalamus (data not shown). A further faint band of a slightly larger size was present in whole brain, cerebellum and cerebral cortex, which suggests alternative splicing of the pre-mRNA that seems to be differently regulated across the human brain.
Immunohistochemistry BRD1-immunostaining showed similar neuronal staining patterns in the adult rat, rabbit and human cortex cerebri (Figure 1 ). The neurons in cortex layers I-VI displayed prominent BRD1 immunoreactivity in the perikaryal cytosol surrounding a weaker granular staining of the nucleus (Figures 1 and 2 ). BRD1 immunoreactivity was likewise seen in the proximal part of the primary dendrites, whereas the distal dendrites and the axon seemed unstained (Figures 1  and 2 ). Glial staining was not noted in the human cerebral cortex or any part of the rat and rabbit CNS. Consecutive sectioning and immunostaining of the rat and rabbit brain confirmed that neuronal BRD1 immunoreactivity was distributed throughout the adult nervous system for example, the cerebrum, brainstem, cerebellum and spinal cord (Figure 3) .
Fetal pig brain tissue of embryonic day 40, 60 ( Figure 4a-c) , 80, 100 and 115 (Figure 4d -f) revealed dense nuclear staining in the neuroepithelial cell layer and the early differentiated neuroblasts (Figure  4a and b) . Medium-differentiated neuroblasts displayed an intense nuclear and perikaryal cytosolar staining pattern (Figure 4c ), while fully differentiated neurons generally stained more weakly and, in particular, had a very weak nuclear staining compared to the staining intensity seen in the perikaryal cytosol (Figures 4d-f) .
mRNA expression in fetal pig brain The level of expression of BRD1 mRNA was measured and normalized to the amount of GAPDH mRNA, which was constantly expressed. While the overall trend in the five examined areas of fetal pig brain was the same, the differences in expression levels were most pronounced in cortex cerebri in particular but also in the regions of the brainstem and basal ganglia ( Figure 5 ). The maximum amount of mRNA was measured at embryonic day 60 in all samples. The two areas that were possible to dissect in the 40-dayold embryo (cortex and cerebellum) showed a lower level of expression. For some areas the abundance of mRNA was also relatively increased at day 80 (brainstem, cortex and basal ganglia). Between embryonic day 80 and 115 BRD1 mRNA expression leveled off. Gene  SNP  S1  M1  M2  S2  S3  S4  S5  S6 S7 S8 S9 S10 S11 S12 S13 
Discussion
Using a case-control sample from Scotland, we have analyzed genes and markers located in a candidate susceptibility locus at the telomeric region of chromosome 22q and found association between the BRD1 gene and both SZ and BPD. Single marker as well as multimarker haplotype associations were observed. One of the BRD1 SNPs (rs138880) and a 'risk' corehaplotype were associated with both disorders while another SNP (rs4468), marker D22S1169 and most of the 'protective' haplotypes were associated primarily with SZ, suggesting that both shared and diseasespecific BRD1 variants may influence disease susceptibility. Although supported by highly significant P-values of gene variants/haplotypes located in a region previously implicated with SZ and BPD by linkage and association studies, the presented association results should be replicated in other populations in order to support this hypothesis. According to data provided by the HapMap project (http://www.hapmap.org/), which is consistent with the LD results presented (Table 4) , BRD1 is located in the centromeric part of a relatively well-defined 150 kb haplotype block containing only one additional gene called ZBED4 (zinc-finger, BED-type containing 4), a widely expressed gene with a yet unknown function. The MLC1 gene is not included in this block, but contained in a B100 kb block more than 130 kb distal to the BRD1 block, and no evidence of LD is observed between the two blocks.
MLC1 was initially proposed as a susceptibility gene for catatonic SZ based on analysis of a single large pedigree. 34 However, both the same group and others have more recently rejected this hypothesis based on more extensive analyses of a number of catatonic families. [35] [36] [37] Interestingly, a recent study of a Southern Indian population reported evidence of association between MLC1 and both SZ and BPD. 38 According to the regional LD pattern discussed above it does not seem likely that the Indian MLC1 signal and the present BRD1 association represent the same susceptibility locus, unless the population of Southern India has a different and more extended LD pattern. However, this might actually be the case as the Indian study also reported association between both disorders and the marker D22S1161, which is located more than 1 cM proximal to BRD1 and MLC1 (http://www.ncbi.nlm.nih.gov/mapview/).
In silico analysis revealed that the BRD1 promoter variant rs138880 affects a putative binding site for the basic helix-loop-helix transcription factor HES1. HES1 appears to repress early embryonic neuronal differentiation of hippocampus, and a downregulation of the transcription factor seems important to normal development. 39 The binding site of HES1 is only present with the C-allele of rs138880, which was over-represented in cases compared to controls and part of the highly significantly associated 2-/3-marker 'risk' core-haplotype. The C-allele, which is the minor allele in humans, appears to be the ancestral allele based on comparison with the chimp genome (http:// www.ncbi.nlm.nih.gov/SNP). This indicates that the allele might have been subject to selection pressure, thus further supporting a possible functional impact of the SNP.
The BRD1 protein was found in neurons of all parts of the CNS examined with a predominant subcellular localization in the nucleus and the perikaryal cytosol. BRD1 contains a bromodomain, a plant homeodomain (PHD) finger, four potential binding sites for nuclear receptors and four predicted nuclear localization signals. 30 Additionally, we have also identified a PWWP-domain (proline-tryptophan-tryptophan-proline) which is approximately 70 amino acids in length and is believed to interact nonspecifically with DNA. 40 Bromodomains are found in a variety of mammalian, invertebrate and yeast DNA-binding proteins, and are able to interact with acetylated lysine on histone proteins. Indeed, a point-mutation of conserved tyrosine residues in the bromodomains of the yeast protein Bdf1 abolishes binding to acetylated histones H3 and H4. 41 They are believed to form a link between acetylated histones and transcriptional activation. The PHD finger is a C4HC3 zinc-finger-like motif found in nuclear proteins thought to be involved in chromatin-mediated transcriptional regulation. The PHD finger motif is reminiscent of, but distinct from the C3HC4 type RING finger. Recently, a model was proposed where adjacent PHD and bromodomains both contact nucleosomes while at the same time interacting with each other. 42 Thus, BRD1 contains a number of motifs pointing towards a possible function as a transcriptional co-factor, which would be in accordance with the subcellular expression pattern observed.
Quantitative expression analysis of BRD1 mRNA in fetal pig brain revealed a temporally and spatially differential profile with high expression at early embryonic stages, in particular in the cortex at embryonic day 60 and 80 ( Figure 5 ). During this period of time the pig cortex is characterized by a high degree of growth and neuronal migration, and the gyration of the cortex is initiated. Immunohistochemistry revealed a variable staining pattern depending on the maturity of the neuronal cell (Figure 4 ). These results suggest that BRD1 expression is highly regulated in the embryonic brain, and as a potential regulator of transcription BRD1 may play a key role in orchestrating important aspects of normal brain development.
In this context, it is interesting that the diseaseassociated promoter SNP (rs138880) affects a possible binding site of the HES1 transcription factor known to be involved in neural differentiation.
Several lines of evidence support the postulate that aberration in brain development and ongoing neuroplasticity are important in the pathogenesis of SZ and increasing evidence also support this hypothesis in BPD. [43] [44] [45] [46] [47] Additionally recent studies have revealed that some of the best replicated SZ susceptibility genes are involved in neurodevelopment. For example neuregulin 1 (NRG1) regulates numerous aspects of neural development and synaptic plasticity, [48] [49] [50] and DISC1 may play an important role in hippocampal and cortical development. [51] [52] [53] [54] Likewise, in BPD a number of studies have supported brain-derived neurotrophic factor (BDNF) as a susceptibility gene, which is involved in promoting and modifying growth, development and survival of neuronal populations. 55 Recent association findings suggest a number of shared susceptibility genes for SZ and BPD, including the neurodevelopmental genes DISC1, NRG1 and BDNF. 56 It is tempting to speculate that impaired neurodevelopment and plasticity may constitute a shared intermediate phenotype for these disorders. The results presented implicating BRD1 with brain development and susceptibility to both SZ and BPD would fit into this hypothesis, and should be interesting to investigate further. Figure 5 Relative quantification of BRD1 mRNA expression in terms of fold changes (2 ÀDDCT and 2 ÀDCT ) found by analysis of variance (left panel) contrasting to embryonic day 115 the mean threshold difference from each of the other days. The significance of the contrasts is indicated (*P < 0.05, **P < 0.01 and ***P < 0.001) with P-values adjusted for the number of contrasts tested using the Sidák method. A polynomial regression model up to third order (right panel) was determined using a forward inclusion stepwise procedure. The significance of the highest order term is indicated.
